This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Castellano, M. Articles by Bohm, M. Search for Related Content PubMed PubMed Citation Articles by Castellano, M. Articles by Bohm, M.

(Hypertension. 1997;29:715-722.)
© 1997 American Heart Association, Inc.

Articles

The Cardiac ß-Adrenoceptor–Mediated Signaling Pathway and Its Alterations in Hypertensive Heart Disease

Maurizio Castellano; Michael Bohm

Scienze Mediche, Universita degli Studi di Brescia (Italy) (M.C.), and Klinik III fur Innere Medizin der Universitat zu Koln (Germany) (M.B.).

Hypertension-induced cardiac hypertrophy is a predictor of the development of cardiac failure. It is unknown which cellular markers contribute to the progression from compensated hypertrophy to failure. In heart failure, several signal transduction defects leading to adenylate cyclase desensitization have been demonstrated, such as ß-adrenoceptor downregulation, increase of inhibitory G protein expression, and uncoupling of ß-adrenergic receptors, presumably by an increase of receptor kinase activity. In hypertensive heart disease, most studies have been performed in rat models of hypertension. As in heart failure, heterologous adenylyl cyclase desensitization occurs. The mechanisms are often different between the heterogeneous models for acquired and genetic hypertension, but G_i protein alterations and ß-adrenoceptor downregulation have been observed frequently. The underlying mechanism for desensitization is most likely a sympathetic activation in established hypertension rather than genetic alterations of signal transduction proteins. The data available suggest that ß-adrenergic desensitization could represent a mechanism that contributes to the progression from hypertrophy to failure. The key question remains whether those hypertensive patients who develop heart failure are more prone to ß-adrenergic desensitization or whether early intervention to reduce sympathetic activity is more effective in preventing or delaying the transition from compensated hypertrophy to overt failure.

Key Words: hypertrophy • sympathetic nervous system • receptors, adrenergic, beta • G proteins • heart failure

This article has been cited by other articles:

				S. M. MacDonnell, G. Garcia-Rivas, J. A. Scherman, H. Kubo, X. Chen, H. Valdivia, and S. R. Houser Adrenergic Regulation of Cardiac Contractility Does Not Involve Phosphorylation of the Cardiac Ryanodine Receptor at Serine 2808 Circ. Res., April 25, 2008; 102(8): e65 - e72. [Abstract] [Full Text] [PDF]

				S. Perlini, I. Ferrero, G. Palladini, R. Tozzi, C. Gatti, M. Vezzoli, F. Cesana, M. B. Janetti, F. Clari, G. Busca, et al. Survival Benefits of Different Antiadrenergic Interventions in Pressure Overload Left Ventricular Hypertrophy/Failure Hypertension, July 1, 2006; 48(1): 93 - 97. [Abstract] [Full Text] [PDF]

				S. M. MacDonnell, H. Kubo, D. L. Crabbe, B. F. Renna, P. O. Reger, J. Mohara, L. A. Smithwick, W. J. Koch, S. R. Houser, and J. R. Libonati Improved Myocardial {beta}-Adrenergic Responsiveness and Signaling With Exercise Training in Hypertension Circulation, June 28, 2005; 111(25): 3420 - 3428. [Abstract] [Full Text] [PDF]

				M. Kozakova, A. G. Fraser, S. Buralli, A. Magagna, A. Salvetti, E. Ferrannini, and C. Palombo Reduced Left Ventricular Functional Reserve in Hypertensive Patients With Preserved Function at Rest Hypertension, April 1, 2005; 45(4): 619 - 624. [Abstract] [Full Text] [PDF]

				F. Labarthe, M. Khairallah, B. Bouchard, W. C. Stanley, and C. Des Rosiers Fatty acid oxidation and its impact on response of spontaneously hypertensive rat hearts to an adrenergic stress: benefits of a medium-chain fatty acid Am J Physiol Heart Circ Physiol, March 1, 2005; 288(3): H1425 - H1436. [Abstract] [Full Text] [PDF]

				D. Bell, A. R. Allen, E. J. Kelso, A. Balasubramaniam, and B. J. McDermott Induction of Hypertrophic Responsiveness of Cardiomyocytes to Neuropeptide Y in Response to Pressure Overload J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 581 - 591. [Abstract] [Full Text] [PDF]

				S. Bartel, B. Hoch, D. Vetter, and E.-G. Krause Expression of Human Angiotensinogen-Renin in Rat: Effects on Transcription and Heart Function Hypertension, February 1, 2002; 39(2): 219 - 223. [Abstract] [Full Text] [PDF]

				U. Schotten, K. Filzmaier, B. Borghardt, S. Kulka, F. Schoendube, C. Schumacher, and P. Hanrath Changes of beta -adrenergic signaling in compensated human cardiac hypertrophy depend on the underlying disease Am J Physiol Heart Circ Physiol, June 1, 2000; 278(6): H2076 - H2083. [Abstract] [Full Text] [PDF]

				C. A. Walker, F. A. Crawford Jr, and F. G. Spinale MYOCYTE CONTRACTILE DYSFUNCTION WITH HYPERTROPHY AND FAILURE: RELEVANCE TO CARDIAC SURGERY J. Thorac. Cardiovasc. Surg., February 1, 2000; 119(2): 388 - 400. [Full Text] [PDF]

				P.A. van Zwieten The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy Cardiovasc Res, January 1, 2000; 45(1): 82 - 91. [Abstract] [Full Text] [PDF]

				N. Dzimiri Regulation of beta -Adrenoceptor Signaling in Cardiac Function and Disease Pharmacol. Rev., September 1, 1999; 51(3): 465 - 502. [Abstract] [Full Text] [PDF]

				E. Cerbai, R. Pino, M. L Rodriguez, and A. Mugelli Modulation of the pacemaker current If by {beta}-adrenoceptor subtypes in ventricular myocytes isolated from hypertensive and normotensive rats Cardiovasc Res, April 1, 1999; 42(1): 121 - 129. [Abstract] [Full Text] [PDF]

				K. M. Anderson, A. D. Eckhart, R. N. Willette, and W. J. Koch The Myocardial ß-Adrenergic System in Spontaneously Hypertensive Heart Failure (SHHF) Rats Hypertension, January 1, 1999; 33(1): 402 - 407. [Abstract] [Full Text] [PDF]

				M. Bohm, M. Castellano, M. Flesch, C. Maack, M. Moll, M. Paul, F. Schiffer, and O. Zolk Chamber-Specific Alterations of Norepinephrine Uptake Sites in Cardiac Hypertrophy Hypertension, November 1, 1998; 32(5): 831 - 837. [Abstract] [Full Text] [PDF]

				L. Levesque and S. T. Crooke Depletion of Protein Kinase C-alpha by Antisense Oligonucleotides Alters Beta-Adrenergic Function and Reverses the Phorbol Ester-Induced Reduction of Isoproterenol-Induced Adenosine 3'-5'-Cyclic Monophosphate Accumulation in Murine Swiss 3T3 Fibroblasts. J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 425 - 434. [Abstract] [Full Text]

				M. Bohm, S. Ettelbruck, M. Flesch, W. H van Gilst, A. Knorr, C. Maack, Y. M Pinto, M. Paul, A. C.H Teisman, and O. Zolk {beta}-Adrenergic signal transduction following carvedilol treatment in hypertensive cardiac hypertrophy Cardiovasc Res, October 1, 1998; 40(1): 146 - 155. [Abstract] [Full Text] [PDF]

				O. Zolk, M. Flesch, G. Nickenig, P. Schnabel, and M. Bohm Alteration of intracellular Ca2+-handling and receptor regulation in hypertensive cardiac hypertrophy: insights from Ren2-transgenic rats Cardiovasc Res, July 1, 1998; 39(1): 242 - 256. [Abstract] [Full Text] [PDF]